CAMLINFINE · Camlin Fine Sciences Ltd · Chemical Manufacturing
CAMLINFINE · Camlin Fine Sciences Ltd · Chemical Manufacturing
As of 06 Nov close
52-week range
62.3% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹520 Cr
Revenue YoY
PAT YoY
-218.4%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.3
P/S (TTM)
1
Sector P/E
19.9
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| CAMLINFINE (this stock) | Not available from data source | 2.3 | +0.3% | +0.6% | 0.69 | 0.0% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Solar Industries India | 100.2 | 26.8 | +17.6% | +31.4% | 13.68 | +0.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
Promoter
stable
FII
stable
MF
5.12% (-1.68pp)
falling 2q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 27 Oct 2026 | Ashish Subhash Dandekar | SELL | 8,10,000 | ₹6.78 Cr |
| 27 Oct 2026 | Ashish Subhash Dandekar | SELL | 5,50,000 | ₹4.61 Cr |
| 22 Sept 2026 | Cyrille Damany | SELL | 10,00,000 | ₹9.75 Cr |
| 29 Jun 2026 | Neeti Santosh Chavan | SELL | 8,000 | ₹10.96 lakh |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- mediumbusiness-standard.com· 04 Nov 2026, 01:28 pmCamlin Fine Sciences tanks 18% post Q2 results; stock hits 52-week low
Concalls & investor presentations
AI-generatedKey takeaway: Camlin Fine Sciences Limited held its Q1 FY27 Earnings Conference Call on August 11, 2026, where management discussed the company's financial performance for the quarter ended June 30, 2026. Management reported revenues of INR 5,199 million, reflecting a 28% increase year-over-year. However, margins were impacted, dropping to 4% due to rising raw material costs and freight expenses. The company has restructured its business into three segments: Specialty Ingredients, Aroma, and Performance Chemicals. Management noted that while the Specialty Ingredients segment performed well, the Aroma segment faced challenges with capacity utilization. The diphenol plant remains shut down for economic reasons, affecting Performance Chemicals. Management guided toward a revenue range of INR 2,200 to INR 2,300 crores for the year, with an EBITDA margin of 10% to 11%. They also mentioned ongoing efforts to manage working capital and the impact of geopolitical factors on raw material prices.
Management highlighted strong revenue growth but acknowledged significant margin pressures.
Sourced from an exchange-filed transcript, dated 17 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Camlin Fine Sciences Limited, dated August 11, 2026, provided an overview of the company's financial performance for the quarter ended June 30, 2026. Management reported a revenue of Rs 5,199 million, reflecting a 27.5% year-over-year increase. The presentation highlighted that the EBITDA for the quarter was Rs 176 million, with an EBITDA margin of 3.4%. Management noted challenges such as higher raw material prices and logistics costs impacting margins. Segmental performance showed significant growth in the Straights and Blends categories, with revenues increasing by 41% and 35% year-over-year, respectively. The company also discussed its strategic acquisitions, including a 100% stake in Vitafor and a majority stake in Vinpai, aimed at expanding its product portfolio and geographical reach. The document emphasized that the presentation was for informational purposes only and did not constitute an offer to purchase securities.
The presentation provided a balanced view of financial performance and challenges without strong emphasis on either positive or negative aspects.
Sourced from an exchange-filed presentation, dated 11 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings conference call for Camlin Fine Sciences Limited on May 26, 2026, discussed the company's audited financial results for the quarter and year ended March 31, 2026. Management reported a revenue of INR 424 crores for the quarter, contributing to a total revenue of INR 1,723 crores, which was impacted by a 20% decline in sales due to shipment delays and increased freight times. The management noted a shift in strategy from selling Straights to Blends, resulting in a 17% growth in the Blends segment. The company also highlighted a gain from the liquidation of its CFS Europe subsidiary, which contributed to a gain of approximately INR 100 crores. Management expressed confidence in the vanillin business, citing improved realizations and a strong order book. However, they acknowledged ongoing challenges related to raw material costs and logistics due to geopolitical tensions.
The management highlighted both growth opportunities and challenges faced by the company.
Sourced from an exchange-filed transcript, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Camlin Fine Sciences Limited, dated May 26, 2026, provided an overview of the company's audited financial results for the quarter and year ended March 31, 2026. The presentation reported a revenue of Rs. 4,248 million for Q4 FY26 and Rs. 17,233 million for FY26. Management noted that the ongoing conflict adversely affected sales in March 2026, impacting raw material availability and increasing logistics costs. The EBITDA for Q4 FY26 was reported at Rs. 212 million, with a margin of 5.0%. The presentation highlighted steady growth in the blends business and the contribution of the newly acquired Vinpai. Management also discussed challenges such as rising interest costs and currency fluctuations. The document outlined plans for improved realizations in the vanillin business and growth in blends across geographies, while cautioning that the lingering conflict may hinder growth in early FY27.
The presentation highlighted both growth opportunities and significant challenges faced by the company.
Sourced from an exchange-filed presentation, dated 26 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings call for Camlin Fine Sciences Limited on February 13, 2026, discussed the company's financial results for the quarter and nine months ended December 31, 2025. Management reported a turnover of Rs. 572 crores, reflecting a 6% increase compared to the same quarter last year. Vanillin sales were highlighted, with management noting a controlled sales strategy to benefit from tariff reductions. The company faced challenges in its Straight business due to declining prices and competition, while the Blends segment showed growth, aided by the acquisition of Vinpai Limited. Management mentioned a fire incident at a blending unit in Brazil, which resulted in inventory loss but indicated that operations would continue. The call also addressed the ongoing liquidation processes in Europe and China, with management expressing confidence in future growth from Vanillin and Blends. Overall, management set a revenue goal of Rs. 2,200 crores for FY'27.
Management reported both growth opportunities and challenges faced in various segments.
Sourced from an exchange-filed transcript, dated 18 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedCamlin Fine Sciences Limited (CAMLINFINE) reported a challenging FY2025-26 with revenue growth to ₹172,330.81 lakh, driven by improved performance in Blends and Aroma Products. However, gross margins declined to 46.47% due to increased competition and subdued global demand, leading to a significant drop in operating EBITDA to ₹10,687.88 lakh. The company incurred a loss after tax of ₹3,296.62 lakh, down from a profit in the previous year. Liquidity pressures were noted, with increased short-term borrowings, though no defaults or insolvency proceedings were reported. The auditor highlighted key audit matters, including exposure to group entities and potential uncertainties in the going concern assumption. The company faces ongoing disputes related to income tax, GST, and excise duties, with some amounts disputed but not overdue. No material weaknesses in internal controls were identified, and the company has not been declared a willful defaulter.
- Revenue grew to ₹172,330.81 lakh, but gross margins fell to 46.47% due to competition and weak demand.
- Operating EBITDA dropped to ₹10,687.88 lakh, and the company reported a loss after tax of ₹3,296.62 lakh.
- Short-term borrowings increased, but no defaults or insolvency proceedings were noted.
- Ongoing disputes with tax authorities (income tax, GST, excise) exist, with some amounts disputed but not overdue.
- No material weaknesses in internal controls were identified, and the company has not been declared a willful defaulter.
Key takeaway: Camlin Fine Sciences Limited faced significant operational and financial challenges in FY2025-26, with declining margins and a substantial loss, despite revenue growth. Ongoing tax disputes and exposure to group entities pose notable risks, though no defaults or insolvency proceedings were reported.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (3 items); Default / Covenant Breach (1 item); Investigation or enforcement mention (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor identified a high risk of significant misstatement in intercompany receivables and payables, which had a significant effect on the company audit.
Regulatory Action
3 occurrencesEarlier (1-3 years ago)
The Supreme People’s Court of China imposed a penalty of RMB 159.32 million on the JV partner in the subsidiary company and others for alleged intellectual property infringement. The subsidiary was attributed 7% of the penalty, amounting to RMB 11.15 million.
Older (3+ years ago)
The Supreme People’s Court of China imposed a penalty of RMB 159.32 million on the company's JV partner Ningbo Wanglong Technology Limited and RMB 11.15 million on CFSWL for alleged intellectual property infringement. The production at CFSWL's facility has been halted pending further court directions.
The Supreme People's Court of China imposed a penalty of RMB 159.32 million (about US$ 25 million / ₹18,000 lakh) on the company's JV partner Wanglong Technology for alleged infringement of intellectual property used in manufacturing Vanillin.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
As of March 31, 2024, the Holding Company has not remitted the amount towards the subscription of 50,000 shares in CFS De Mexico Blends S.A.P.I. DE C.V., a wholly owned subsidiary.
Investigation or enforcement mention
1 occurrenceEarlier (1-3 years ago)
Britec SA, a wholly owned step-down subsidiary incorporated in Guatemala, detected embezzlement by an employee in bank accounts aggregating to ₹640.48 lakh during the year under review.
Routine disclosures
Internal Control Weakness
1 occurrenceRecent (last 12 months)
The auditor identified a material weakness in the company's internal financial controls over financial reporting.
Contingent Liability
5 occurrencesRecent (last 12 months)
The company has unearned premium on financial guarantees given to subsidiaries amounting to 27.1 lakh as of March 31, 2026.
Earlier (1-3 years ago)
The Holding Company has a contingent liability of ₹1,712.31 lakh related to compensation attributed by the National Green Tribunal (NGT) for alleged environmental violations at Tarapur MIDC, with ₹515.56 lakh required to be deposited as per court orders, though only ₹154.97 lakh has been deposited so far.
The company has outstanding interest dues on delayed payments to a micro enterprise, with amounts remaining due and payable in succeeding years until the interest is actually paid, as per the Micro, Small and Medium Enterprises Development Act, 2006.
Older (3+ years ago)
The company has unclaimed public deposits and unclaimed interest on public deposits outstanding as of March 31, 2022, which were transferred to the Investor Education and Protection Fund during the year.
The company has secured loans of ₹17,322.15 lakh and ₹642.05 lakh, guaranteed by Mr. Ashish Dandekar, and these are secured by charges over the company's assets. However, there is a mention of no certification in relation to the satisfaction of charge received from the banks pending for submission with ROC.
Related-Party Transaction
4 occurrencesRecent (last 12 months)
The company has transactions with related parties including Hardware Renaissance Inc, Clean Max Sundarban Pvt. Ltd, and others, involving sales of products, compensation to KMP, and investments.
Earlier (1-3 years ago)
The company has disclosed transactions with related parties during the year, including entities under the control or significant influence of Key Management Personnel (KMP) and their relatives, such as Fine Renewable Energy Limited, Abana Medisys Private Limited, Pagoda Advisors Private Limited, Hardware Renaissance Inc, and Kokuyo Camlin Ltd.
Older (3+ years ago)
The company has disclosed transactions with related parties, including sales of products to entities like CFS Europe S.P.A, CFS do Brazil, and CFS North America LLC, and services availed from entities like Chemolutions Chemicals Limited and Hardware Renaissance Inc, with amounts specified in lakhs for the years ended March 31, 2023, and 2022.
The company has provided a list of related parties, including subsidiaries and other entities, as required by Ind AS 24.
Management & Board Governance
1 occurrenceOlder (3+ years ago)
Sarvjit Bedi resigned as a Non-Executive Director (Independent) effective April 19, 2023. Thomas Videbaek resigned as a Non-Executive Director (Independent) effective February 23, 2023.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
14.37% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).